Catalyst Wire Dossier Catalyst Wire Dossier

StromaForte

human allogeneic bone-marrow-derived mesenchymal stromal cells · Cellcolabs Clinical SPV Limited
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for StromaForte, covering 2026-04-16 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis [Phase 2, Phase 3]

See pricing